MedTrace Logo

Tadalafil for Sarcoidosis Associated Pulmonary Hypertension

NCT01324999 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-07-24

Study results available
· View outcomes & findings →

Summary

This study is designed to assess safety and efficacy of tadalafil in patients with Sarcoidosis Associated Pulmonary Hypertension.

Hypothesis: Tadalafil is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis

Conditions

  • Pulmonary Hypertension

Interventions

DRUG

Tadalafil

20mg/day for one month then 40mg/day for additional 4 months

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • United Therapeutics

    collaborator INDUSTRY

  • University of Cincinnati

    collaborator OTHER

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • Hubert J Ford, M.D. · University of North Carolina, Chapel Hill

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2013-07-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01324999 on ClinicalTrials.gov